, Tracking Stock Market Picks
Enter Symbol:
Somaxon Pharmaceuticals, Inc. (SOMX) [hlAlert]

down 94.36 %

Somaxon Pharmaceuticals, Inc. (SOMX) rated Buy

Posted on: Thursday,  Nov 8, 2007  9:25 AM ET by Friedman Billings

Friedman Billings rated Buy Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) on 11/08/2007, when the stock price was $53.20. Since
then, Somaxon Pharmaceuticals, Inc. has lost 94.36% as of 03/06/2015's recent price of $3.00.
If you would have followed this Friedman Billings's recommendation on SOMX, you would have lost 94.36% of your investment in 2675 days.

Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon's lead product candidate, SILENOR, is in Phase III clinical trials for the treatment of insomnia

FBR Capital Markets is a full service investment banking, institutional sales, trading and research and asset management firm with a customer-focused and innovative approach to meeting its clients needs. It focuses its banking, advisory, trading and research efforts on seven broad industry sectors including consumer, diversified industrials, energy & natural resources, financial institutions, insurance, real estate and technology, media & telecom. With our headquarters in the Washington, D.C. metropolitan area, our Economic and Washington Policy Analysis groups offer clients a comprehensive overview of national economic trends along with a unique perspective on the impact that legislation and regulation will have on industry sectors and individual companies
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/8/2007 9:25 AM Buy
53.20 112.00
as of 8/27/2015
1 Week   
1 Month   
3 Months   
1 YTD down  -90.96 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy